Harrow Advances TRIESENCE into Phase 3 Trial for Post-Cataract Inflammation

Event summary

  • Harrow's Phase 3 trial for TRIESENCE in post-cataract inflammation cleared by FDA, set to begin Q1 2026.
  • Study aims to enroll 250 patients, randomized 2:1 (TRIESENCE:placebo), with primary endpoints at Days 8 and 14.
  • TRIESENCE targets growing demand for dropless cataract surgery solutions, per Market Scope surveys.
  • Success could expand TRIESENCE's label, reinforcing Harrow's strategy for streamlined surgical care.

The big picture

Harrow's Phase 3 trial aligns with a broader shift toward dropless cataract surgery, driven by surgeon preference and patient compliance challenges. With 4 million annual U.S. procedures, the market presents significant scale for solutions that simplify post-operative care. Success could position TRIESENCE as a cornerstone of Harrow's portfolio, reinforcing its focus on efficiency and patient outcomes.

What we're watching

Regulatory Success
Whether TRIESENCE clears Phase 3, enabling label expansion and broader adoption.
Market Penetration
The pace at which dropless cataract solutions gain traction amid surgeon/patient demand.
Commercial Strategy
How Harrow leverages TRIESENCE data to differentiate in a competitive ophthalmic space.